Matinas BioPharma

Yahoo Finance • 2 months ago

What's going on in today's session

Intrigued by the market activity one hour before the close of the markets on Monday? Uncover the key winners and losers of today's session in our insightful analysis. [topmovers] TODAY'S TOP GAINERS TICKER CHANGE COMMENT SNGX... Full story

Yahoo Finance • 2 months ago

In today's session, these stocks are experiencing unusual volume.

Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume. [unusualvolume] UNUSUAL VOLUME STOCKS TICKER CHANGE COMMENT VMAR [https://www.chartmill.com/stock/quote/VMAR/profile]... Full story

Yahoo Finance • 2 months ago

Monday's session: top gainers and losers

Curious to know what's happening on the US markets in the middle of the day on Monday? Join us as we explore the top gainers and losers in today's session. [topmovers] GAINERS TICKER CHANGE COMMENT SNGX [https://www.chartmill... Full story

Yahoo Finance • 2 months ago

Let's uncover which stocks are experiencing notable gaps during today's session.

Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Monday. Let's explore the market movements and identify the stocks with significant gaps. [gap] TOP GAP UP STOCKS TICKER CHANGE COM... Full story

Yahoo Finance • 2 months ago

These stocks are moving in today's pre-market session

As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. [premarket] PRE-MARKET GAINERS TICKER CHANGE COMMENT V... Full story

Yahoo Finance • 2 months ago

Wondering what's happening in today's after-hours session?

Discover the top movers in Friday's after-hours session and stay informed about the post-market dynamics. [postmarket] TODAY'S AFTER HOURS GAINERS TICKER CHANGE COMMENT DHAI [https://www.chartmill.com/stock/quote/DHAI/profile... Full story

Yahoo Finance • 2 months ago

Top movers in Friday's session

Looking for insights into the US markets one hour before the close of the markets on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. [topmovers] TOP GAINERS TICKER CHANGE CO... Full story

Yahoo Finance • 2 months ago

Top movers analysis in the middle of the day on 2025-08-15: top gainers and losers in today's session.

Curious to know what's happening on the US markets in the middle of the day on Friday? Join us as we explore the top gainers and losers in today's session. [topmovers] TODAY'S TOP GAINERS TICKER CHANGE COMMENT DFLIW [https://... Full story

Yahoo Finance • 2 years ago

Why Matinas BioPharma Stock Is Sinking Today

BioNTech SE (NASDAQ: BNTX) and Matinas BioPharma Holdings Inc (NYSE: MTNB) have ended an mRNA-based collaboration. Matinas reported the update in its Q1 earnings release. The exclusive collaboration with BioNTech was announced just a year... Full story

Yahoo Finance • 2 years ago

Compassionate Use Patient Treated with Matinas BioPharma’s MAT2203 and Showing Complete Clinical Resolution of Rare R. mucilaginosa Fungal Infection Featured in Oral Presentation at ECCMID

BEDMINSTER, N.J., April 18, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery t... Full story

Yahoo Finance • 3 years ago

Matinas BioPharma to Webcast Conference Call to Discuss 2022 Financial Results and Provide a Business Update on March 15, 2023

BEDMINSTER, N.J., March 08, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules... Full story

Yahoo Finance • 3 years ago

Matinas BioPharma Announces that MAT2203 Will Be Featured in Two Oral Presentations at ECCMID

BEDMINSTER, N.J., March 02, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery t... Full story

Yahoo Finance • 3 years ago

Matinas BioPharma to Provide Corporate Update and 2023 Business Outlook on January 30, 2023

BEDMINSTER, N.J., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nano... Full story

Yahoo Finance • 3 years ago

12 Hot Penny Stocks On the Rise

In this article, we discuss 12 hot penny stocks on the rise. If you want to see more stocks in this selection, check out 5 Hot Penny Stocks On the Rise. Penny stocks usually trade under $5 and are favored by new investors or market partic... Full story

Yahoo Finance • 3 years ago

Matinas BioPharma Announces Collaboration with National Resilience to Explore and Evaluate Novel LNC Platform Delivery Technology for Certain Nucleic Acids

BEDMINSTER, N.J., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nano... Full story

Yahoo Finance • 3 years ago

Matinas BioPharma Reports Third Quarter 2022 Financial Results and Highlights Recent Progress

EnACT Phase 2 study of MAT2203 in cryptococcal meningitis met its primary endpoint with 95% two-week patient survival in the Cohort 4 all-oral regimen Phase 3 pivotal trial of MAT2203 for treatment of cryptococcal meningitis to commence Q... Full story

Yahoo Finance • 3 years ago

Matinas BioPharma Announces Positive Interim Data from the Phase 2 EnACT Trial of MAT2203 for the Treatment of Cryptococcal Meningitis, Exceeding Primary Endpoint Threshold; Patient Survival in All-Oral Cohort 4 Regimen Currently 90%

Two-week survival in Cohort 4 (all-oral regimen) was 95% in 40 patients receiving MAT2203 Mean Early Fungicidal Activity (EFA) of the rate of yeast clearance in cerebrospinal fluid exceeded the prespecified primary endpoint threshold of >... Full story

Yahoo Finance • 3 years ago

Matinas BioPharma to Present at the ThinkEquity Annual Global Investment Conference

Matinas BioPharma Holdings, Inc. BEDMINSTER, N.J., Oct. 21, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and smal... Full story

Yahoo Finance • 3 years ago

Matinas BioPharma to Webcast Conference Call Discussing First Quarter 2022 Financial and Operational Results on May 12, 2022

Matinas BioPharma Holdings, Inc. BEDMINSTER, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic... Full story